Should you stay common tabs on pharmaceutical large Pfizer (PFE +1.36%), you then understand it hasn’t but restored the income misplaced because of the wind-down of the COVID-19 pandemic; the sector simply does not want its vaccine (Comirnaty) or its an infection remedy (Paxlovid) up to it did in 2022, when the corporate’s height line surged to only over $100 billion. Ultimate yr’s reported income used to be handiest $62.6 billion.
You may additionally know that Pfizer’s top-selling medication, just like the blood thinner Eliquis and most cancers remedies Ibrance and Xtandi, will lose their patent coverage subsequent yr, whilst the patent for its pneumonia vaccine Prevnar 13 is even closer its finish. Those 3 medication on my own accounted for over $20 billion of 2025 income.
Attach the dots: Buyers apprehensive that Pfizer would possibly not be capable of proceed paying its dividend are not unwarranted of their worry. Stocks have carried out accordingly.
These days’s Alternate
(1.36%) $0.35
Present Value
$26.04
Key Knowledge Issues
Marketplace Cap
$148B
Day’s Vary
$25.79 – $26.21
52wk Vary
$23.11 – $28.75
Quantity
32.2M
Avg Vol
36.9M
Gross Margin
65.16%
Dividend Yield
6.61%
A up to date deal struck with China-based biopharma outfit Innovent Biologics (IVBXF 1.43%), then again, must alleviate no less than a few of this concern. And it must ease lots of the issues source of revenue buyers have at the moment, if this partnership serves as a fashion for long run ones.
Taking the most obvious steps
It is not as though Pfizer has been ignoring its march towards some key patent cliff, for the report. It is been performing. In November 2025, the drugmaker finished its acquisition of Metsera, garnering its anti-obesity drug applicants. In 2023, it shelled out $43 billion for Seagen, bringing a handful of promising most cancers medication to the desk. The 2022 purchases of International Blood Therapeutics, Biohaven Pharmaceutical Protecting, and ReViral started the hot fill up of the corporate’s pipeline and portfolio.
And there is self belief in those acquisitions. With plans to start out more or less 20 pivotal drug trials this yr, CEO Albert Bourla commented all over remaining month’s first-quarter income convention name: “Our contemporary agreement agreements resolving infringement of patent associated with Vyndamax [for the treatment of transthyretin-mediated amyloid cardiomyopathy] have the prospective to modify the expansion profile of the corporate considerably post-2028. This provides us higher self belief that beginning in 2029, we can input a five-year duration of high-single-digit income CAGR [compound annual growth rate].”
The settlement inked with Innovent Biologics, although, isn’t the same as any of the corporate’s contemporary acquisitions in that it is not an outright acquisition in any respect. It is a partnership that may praise the 2 individuals’ shared luck, with out enforcing the chance of punishing a suitor for spending an excessive amount of on what may finally end up being a disappointing drug lineup.
Other strengths
The cooperation in the end comes to 12 other promising most cancers medication, 8 of that have been evolved by means of Innovent, and 4 of which is able to come from Pfizer. The 2 corporations will co-develop and co-market any of those medication that in the end win approval right here and/or in a foreign country. Importantly, Innovent Biologics enjoys get entry to to China’s marketplace that Pfizer would possibly not, whilst Pfizer has a powerful succeed in in maximum different portions of the sector that Innovent may now not be capable of smash into by itself.
Symbol supply: Getty Pictures.
It is the greenback quantities of the partnership which might be so encouraging, or extra in particular, the way in which doable long run bills are structured. Despite the fact that it is being billed as a $10.5 billion deal, Pfizer handiest owes Innovent $650 million up entrance. The opposite $9.85 billion will handiest be paid as — and if — developmental, regulatory, and commercialization milestones are met. In different phrases, each pharmaceutical corporations have an incentive to proceed doing their easiest paintings.
That is against this with Pfizer’s pricey acquisition of Seagen, or the $10 billion deal it made for Metsera. Each purchases caused some complaint over their steep costs, in addition to the reasonably early developmental phases of every goal corporate’s medication. In reality, Pfizer lately ended early-stage trials of Seagen’s SGN-BB228 (PF-08046049) and antibody-drug conjugate PF-08046045, vindicating those criticisms.
Larger dividend yield, larger possibility
This kind of (nearly) 50-50 developmental dealmaking with Innovent Biologics is not remarkable inside the drug building enviornment, even if it’s much less not unusual. The query stays, then again: How does Pfizer’s settlement with Innovent spice up its skill to proceed paying its dividend?
Whilst the precise fiscal specifics are nonetheless unknowable at this level, the intuitive resolution could also be the precise one: This partnership is a win for Pfizer (and for Innovent), as it provides each companions a possibility at long run money drift with out forcing both to pony up a number of cash to outright personal a drug portfolio that may now not supply ok payback on its price ticket. It would not be fallacious to think about this as a hedge.
Simply do not lose standpoint. To offset the $60.5 billion price of long-term debt that is costing it $670 million in hobby expense each and every quarter — debt that is just about doubled simply for the reason that finish of 2022, even supposing income has fallen 40% all over this time — Pfizer will wish to make no less than a pair extra equivalent offers to actually solidify its skill to fund the dividend whilst now not undermining its skill to develop its industry. It is suffering to do each at the moment.
PFE EPS Diluted (Quarterly) information by means of YCharts.
Sure, Pfizer and its dividend can live on the patent cliff at the horizon. However the “five-year duration of high-single-digit income CAGR” that Bourla discussed can not get the activity achieved successfully by itself, since maximum of this income could also be prone to require stepped-up spending (together with medical trials and advertising) to power it.
Partnerships like the only with Innovent Biologics are how Pfizer can produce much-needed lower-cost income expansion. It simply wishes extra of them. Most effective time will inform if we get them, although, making Pfizer inventory a reasonably riskier source of revenue prospect than some buyers will wish to take a shot on.
After all, with a forward-looking dividend yield of 6.7%, no less than they are being neatly compensated for taking over somewhat extra possibility.
